• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人眼和复杂性中心性浆液性脉络膜视网膜病变(CSCR)眼中的眼类固醇组。

Ocular steroidome in human eyes and in eyes with complex central serous chorioretinopathy (CSCR).

机构信息

Department of Ophthalmology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris Cité, Paris, France.

Centre de Recherche des Cordeliers, INSERM, Physiopathology of Ocular Diseases: Therapeutic Innovations, University Paris Cité, Paris, France.

出版信息

Sci Rep. 2023 Aug 29;13(1):14111. doi: 10.1038/s41598-023-41126-0.

DOI:10.1038/s41598-023-41126-0
PMID:37644063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10465571/
Abstract

The exact link between systemic and ocular endogenous corticoids (steroidome) is unclear and whether the ocular steroidome is altered in CSCR eyes is unknown. The aims of this study were to analyze the human steroidome in the aqueous humor as a function of age, sex and time of the day, to correlate systemic and ocular steroidome and to analyze the ocular steroidome in long lasting complex inactive CSCR. Based on our results, we present two CSCR cases treated by the combination of oral mineralocorticoid antagonist and glucocorticoids drops. In a cross-sectional study, aqueous humor (AH) was collected between 8am and 6 pm from 50 unaffected individuals (25 men and 25 women) and from 14 patients with chronic CSCR, during cataract surgery. In addition, simultaneous serum and AH were collected from 27 individuals undergoing cataract surgery and, simultaneous AH and vitreous were collected from 9 patients undergoing cataract and vitrectomy to estimate corticoids levels in the different compartments. The steroidome was determined using a LC-MS/MS method that quantifies 13 endogenous corticoids from the gluco, mineralocorticoid and androgen pathways. In AH and vitreous, the highest corticoid level is reached by cortisol (F), that represents less than 10% of F serum level. The cortisol levels in the serum did not correlate with ocular cortisol levels. Serum and ocular cortisone (E) levels correlate, although less than 5% of circulating E reaches the eye. The only mineralocorticoids measured in the AH were corticosterone (B) and its inactive form, the 11-desoxycorticosterone (A). There was no influence of circadian rhythm on cortisol ocular levels and there was no correlation between the age or the sex and the level of F, E, A, and B. In eyes with chronic inactive CSCR, the levels of the active glucocorticoid form F was lower than in control eyes and the F/E ratio was reduced by 50% but the B/A ratio was higher indicating imbalance towards active mineralocorticoids. Base on this observation, we propose to combine an antagonist of the mineralocorticoid receptor together with topical glucocorticoids in two CSCR patients, resistant to all other treatments, with favorable outcome. Our results indicate that the ocular psteroidome is highly regulated suggesting a local metabolism of ocular corticoids. In eyes with long-lasting complex inactive CSCR, the steroidome analysis shows lower active glucocorticoids and higher active mineralocorticoids.

摘要

内源性系统性和眼内皮质激素(类固醇组)之间的确切联系尚不清楚,CSCR 眼内的眼内类固醇组是否发生改变也尚不清楚。本研究的目的是分析房水中的人体类固醇组作为年龄、性别和时间的函数,以关联系统性和眼内类固醇组,并分析长期持续的复杂非活动性 CSCR 中的眼内类固醇组。基于我们的结果,我们提出了两种 CSCR 病例,通过联合口服盐皮质激素拮抗剂和糖皮质激素滴注进行治疗。在一项横断面研究中,在白内障手术期间,于上午 8 点至下午 6 点从 50 名无影响个体(25 名男性和 25 名女性)和 14 名慢性 CSCR 患者中收集房水(AH)。此外,同时从 27 名接受白内障手术的个体中收集血清和 AH,并从 9 名接受白内障和玻璃体切除术的患者中同时收集 AH 和玻璃体,以估计不同隔室中的皮质激素水平。使用 LC-MS/MS 方法测定类固醇组,该方法定量测定来自葡糖、盐皮质激素和雄激素途径的 13 种内源性皮质激素。在 AH 和玻璃体中,皮质醇(F)达到最高皮质激素水平,F 仅占血清 F 水平的不到 10%。血清皮质醇水平与眼内皮质醇水平不相关。血清和眼内可的松(E)水平相关,尽管不到 5%的循环 E 到达眼睛。在 AH 中测量的唯一盐皮质激素是皮质酮(B)及其无活性形式 11-去氧皮质酮(A)。昼夜节律对皮质醇眼内水平没有影响,年龄或性别与 F、E、A 和 B 的水平之间没有相关性。在患有慢性非活动性 CSCR 的眼中,活性糖皮质激素形式 F 的水平低于对照眼中,F/E 比值降低了 50%,但 B/A 比值升高,表明向活性盐皮质激素的平衡发生了变化。基于这一观察结果,我们建议在两名对所有其他治疗均有抵抗力的 CSCR 患者中联合使用盐皮质激素受体拮抗剂和局部糖皮质激素治疗,结果良好。我们的结果表明,眼内 psteroidome 受到高度调节,表明眼内皮质激素的局部代谢。在长期持续的复杂非活动性 CSCR 眼中,类固醇组分析显示活性糖皮质激素较低,活性盐皮质激素较高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/96cf070f0ede/41598_2023_41126_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/4fe94330442c/41598_2023_41126_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/f0063d61db83/41598_2023_41126_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/a6aa096d2af1/41598_2023_41126_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/40f884e80616/41598_2023_41126_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/157a23368ba0/41598_2023_41126_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/c3e138127274/41598_2023_41126_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/a391dd13069b/41598_2023_41126_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/3b256572c6a7/41598_2023_41126_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/a09cc55b7e96/41598_2023_41126_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/96cf070f0ede/41598_2023_41126_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/4fe94330442c/41598_2023_41126_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/f0063d61db83/41598_2023_41126_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/a6aa096d2af1/41598_2023_41126_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/40f884e80616/41598_2023_41126_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/157a23368ba0/41598_2023_41126_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/c3e138127274/41598_2023_41126_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/a391dd13069b/41598_2023_41126_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/3b256572c6a7/41598_2023_41126_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/a09cc55b7e96/41598_2023_41126_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a8c/10465571/96cf070f0ede/41598_2023_41126_Fig10_HTML.jpg

相似文献

1
Ocular steroidome in human eyes and in eyes with complex central serous chorioretinopathy (CSCR).人眼和复杂性中心性浆液性脉络膜视网膜病变(CSCR)眼中的眼类固醇组。
Sci Rep. 2023 Aug 29;13(1):14111. doi: 10.1038/s41598-023-41126-0.
2
Chronic Systemic Dexamethasone Regulates the Mineralocorticoid/Glucocorticoid Pathways Balance in Rat Ocular Tissues.慢性全身给予地塞米松调节大鼠眼组织盐皮质激素/糖皮质激素通路的平衡。
Int J Mol Sci. 2022 Jan 24;23(3):1278. doi: 10.3390/ijms23031278.
3
Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis.中心性浆液性脉络膜视网膜病变:最新发现与新病理生理学假说。
Prog Retin Eye Res. 2015 Sep;48:82-118. doi: 10.1016/j.preteyeres.2015.05.003. Epub 2015 May 27.
4
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.醛固酮受体参与大鼠和人眼脉络膜视网膜病变。
J Clin Invest. 2012 Jul;122(7):2672-9. doi: 10.1172/JCI61427. Epub 2012 Jun 11.
5
Effect of eplerenone on choroidal blood flow changes during isometric exercise in patients with chronic central serous chorioretinopathy.依普利酮对慢性中心性浆液性脉络膜视网膜病变患者等长运动时脉络膜血流变化的影响。
Acta Ophthalmol. 2021 Dec;99(8):e1375-e1381. doi: 10.1111/aos.14809. Epub 2021 Mar 1.
6
Low incidence of pachydrusen in central serous chorioretinopathy in an Indian cohort.在印度队列中,中心性浆液性脉络膜视网膜病变中出现厚盘的发生率较低。
Indian J Ophthalmol. 2020 Jan;68(1):118-122. doi: 10.4103/ijo.IJO_528_19.
7
Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.盐皮质激素受体拮抗剂治疗中心性浆液性脉络膜视网膜病变:一项随机对照试验的荟萃分析
Ophthalmol Retina. 2019 Feb;3(2):154-160. doi: 10.1016/j.oret.2018.09.003. Epub 2018 Sep 15.
8
[Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy].[盐皮质激素受体拮抗剂作为急性和慢性中心性浆液性脉络膜视网膜病变的治疗选择]
Ophthalmologe. 2014 Feb;111(2):173-80. doi: 10.1007/s00347-013-3001-0.
9
A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的多中心长期疗效研究
Am J Ophthalmol. 2016 Oct;170:91-99. doi: 10.1016/j.ajo.2016.07.026. Epub 2016 Aug 9.
10
Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serous Chorioretinopathy.联合局部抗炎与口服乙酰唑胺治疗中心性浆液性脉络膜视网膜病变
Optom Vis Sci. 2019 Jul;96(7):500-506. doi: 10.1097/OPX.0000000000001394.

引用本文的文献

1
Interventions for central serous chorioretinopathy: a network meta-analysis.中心性浆液性脉络膜视网膜病变的干预措施:一项网状Meta分析
Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
2
Salivary steroids in acute central serous chorioretinopathy.急性中心性浆液性脉络膜视网膜病变中的唾液类固醇
Int Ophthalmol. 2025 Jan 29;45(1):49. doi: 10.1007/s10792-025-03422-8.
3
Differential Effect of Aldosterone or Mineralocorticoid Receptor Overexpression on Retinal Inflammation.醛固酮或盐皮质激素受体过表达对视网膜炎症的差异影响。

本文引用的文献

1
First Evidence Indicates the Physiology- and Axial-Myopia-Dependent Profiles of Steroid Hormones in Aqueous Humor.首个证据表明房水中类固醇激素的生理及轴性近视依赖型特征。
Metabolites. 2022 Dec 5;12(12):1220. doi: 10.3390/metabo12121220.
2
Topical Dexamethasone as an Adjuvant to Mineralocorticoid Receptor Antagonists for the Treatment of Recalcitrant Central Serous Chorioretinopathy.外用地塞米松作为盐皮质激素受体拮抗剂的辅助药物用于治疗顽固性中心性浆液性脉络膜视网膜病变
Ophthalmic Surg Lasers Imaging Retina. 2022 Dec;53(12):659-665. doi: 10.3928/23258160-20221115-02. Epub 2022 Dec 1.
3
Clinical Characteristics and Multimodal Imaging Findings of Central Serous Chorioretinopathy in Women versus Men.
Invest Ophthalmol Vis Sci. 2024 Oct 1;65(12):39. doi: 10.1167/iovs.65.12.39.
4
Influence of scleral thickness on photodynamic therapy outcomes in central serous chorioretinopathy.巩膜厚度对中心性浆液性脉络膜视网膜病变光动力疗法疗效的影响。
Acta Ophthalmol. 2025 May;103(3):e165-e175. doi: 10.1111/aos.16779. Epub 2024 Oct 20.
5
PREDNISOLONE EYE DROPS AS A POTENTIAL TREATMENT IN NONNEOVASCULAR PACHYCHOROID-RELATED DISEASES.泼尼松龙滴眼液作为一种治疗非新生血管性相关疾病的潜在疗法。
Retina. 2024 Aug 1;44(8):1371-1378. doi: 10.1097/IAE.0000000000004109.
女性与男性中心性浆液性脉络膜视网膜病变的临床特征及多模态影像学表现
J Clin Med. 2022 Mar 19;11(6):1706. doi: 10.3390/jcm11061706.
4
Chronic Systemic Dexamethasone Regulates the Mineralocorticoid/Glucocorticoid Pathways Balance in Rat Ocular Tissues.慢性全身给予地塞米松调节大鼠眼组织盐皮质激素/糖皮质激素通路的平衡。
Int J Mol Sci. 2022 Jan 24;23(3):1278. doi: 10.3390/ijms23031278.
5
Mineralocorticoid pathway in retinal health and diseases.视网膜健康与疾病中的盐皮质激素通路。
Br J Pharmacol. 2022 Jul;179(13):3190-3204. doi: 10.1111/bph.15770. Epub 2022 Jan 28.
6
Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application.地塞米松磷酸钠经眼部给药后进入人房水的渗透动力学。
Int J Clin Pract. 2021 Dec;75(12):e14987. doi: 10.1111/ijcp.14987. Epub 2021 Oct 26.
7
Validation of central serous chorioretinopathy multimodal imaging-based classification system.基于多模态成像的中心性浆液性脉络膜视网膜病变分类系统的验证。
Graefes Arch Clin Exp Ophthalmol. 2022 Apr;260(4):1161-1169. doi: 10.1007/s00417-021-05452-1. Epub 2021 Oct 20.
8
11βHSD2 Efficacy in Preventing Transcriptional Activation of the Mineralocorticoid Receptor by Corticosterone.11β-羟类固醇脱氢酶2在预防皮质酮对盐皮质激素受体转录激活中的作用
J Endocr Soc. 2021 Sep 3;5(11):bvab146. doi: 10.1210/jendso/bvab146. eCollection 2021 Nov 1.
9
Pathogenic Effects of Mineralocorticoid Pathway Activation in Retinal Pigment Epithelium.盐皮质激素信号通路激活对视网膜色素上皮细胞的致病作用
Int J Mol Sci. 2021 Sep 5;22(17):9618. doi: 10.3390/ijms22179618.
10
Mineralocorticoid Receptor Pathway and Its Antagonism in a Model of Diabetic Retinopathy.糖尿病视网膜病变模型中的盐皮质激素受体通路及其拮抗作用。
Diabetes. 2021 Nov;70(11):2668-2682. doi: 10.2337/db21-0099. Epub 2021 Aug 23.